Mourad Majidi

982 total citations
17 papers, 656 citations indexed

About

Mourad Majidi is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mourad Majidi has authored 17 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Mourad Majidi's work include Cancer Immunotherapy and Biomarkers (5 papers), Immune Cell Function and Interaction (4 papers) and Immunotherapy and Immune Responses (4 papers). Mourad Majidi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Immune Cell Function and Interaction (4 papers) and Immunotherapy and Immune Responses (4 papers). Mourad Majidi collaborates with scholars based in United States, China and Japan. Mourad Majidi's co-authors include Hildegard M. Schuller, Hussein A.N. Al-Wadei, Jack A. Roth, Bingliang Fang, Lin Ji, Ismail M. Meraz, Bingbing Dai, Maria Cekanova, Feng Meng and Takashi Takahashi and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Mourad Majidi

15 papers receiving 650 citations

Peers

Countries citing papers authored by Mourad Majidi

Since Specialization

Citations

This map shows the geographic impact of Mourad Majidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mourad Majidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mourad Majidi more than expected).

Fields of papers citing papers by Mourad Majidi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mourad Majidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mourad Majidi. The network helps show where Mourad Majidi may publish in the future.

Co-authorship network of co-authors of Mourad Majidi

This figure shows the co-authorship network connecting the top 25 collaborators of Mourad Majidi. A scholar is included among the top collaborators of Mourad Majidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mourad Majidi. Mourad Majidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 2025 ·eLife ·Ismail M. Meraz, Mourad Majidi, Renduo Song, (unknown), Lihui Gao, Qi Wang, Jing Wang, Elizabeth J. Shpall, Jack A. Roth	3
2	NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 2024 ·eLife ·Ismail M. Meraz, Mourad Majidi, Renduo Song, (unknown), Lihui Gao, Qi Wang, Jing Wang, (unknown), Jack A. Roth	1
3	TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model 2022 ·Communications Biology ·Ismail M. Meraz, Mourad Majidi, Ruping Shao, Feng Meng, Min Jin Ha, Elizabeth J. Shpall, Jack A. Roth	16
4	Abstract 1105: Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC 2021 ·Cancer Research ·Ismail M. Meraz, Mourad Majidi, Ruping Shao, Lihui Gao, (unknown), Huiqin Chen, Min Jin Ha, Jack A. Roth	0
5	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses 2019 ·Cancer Immunology Research ·Ismail M. Meraz, Mourad Majidi, Feng Meng, (unknown), Min Jin Ha, Shinya Neri, Bingliang Fang, Steven H. Lin, Peggy T. Tinkey, Elizabeth J. Shpall, Jeffrey S. Morris, Jack A. Roth	108
6	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells 2019 ·Oncogene ·Apar Pataer, Bülent Özpolat, (unknown), Neil R. Cashman, Steven S. Plotkin, Charles E. Samuel, Steven H. Lin, Nashwa Kabil, Jing Wang, Mourad Majidi, Bingliang Fang, Jack A. Roth, Ara A. Vaporciyan, Ignacio I. Wistuba, Mien‐Chie Hung, Stephen G. Swisher	21
7	TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras -Mutant Mouse Lung Cancer Models 2018 ·Cancer Immunology Research ·Ismail M. Meraz, Mourad Majidi, Xiaobo Cao, Heather Lin, Lerong Li, Jing Wang, Veera Baladandayuthapani, David C. Rice, Boris Sepesi, Lin Ji, Jack A. Roth	42
8	Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics 2017 ·Oncotarget ·Emanuela Gentile, Taro Oba, Jing Lin, Ruping Shao, Feng Meng, Xiaobo Cao, Heather Lin, Mourad Majidi, Apar Pataer, Veerabhadran Baladandayuthapani, Dong Cai, Jack A. Roth, Lin Ji	6
9	Abstract 621: Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in lung cancer syngeneic mouse models 2017 ·Cancer Research ·Ismail M. Meraz, Mourad Majidi, Ruping Shao, (unknown), Xiaobo Cao, David C. Rice, Boris Sepesi, Lin Ji, Jack A. Roth	1
10	TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC) 2017 ·Oncotarget ·Xiaobo Cao, Yang Zhao, Jing Wang, Bingbing Dai, Emanuela Gentile, Jing Lin, Xingxiang Pu, Lin Ji, Shuhong Wu, Ismail M. Meraz, Mourad Majidi, Jack A. Roth	20
11	TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin 2016 ·Scientific Reports ·(unknown), Mourad Majidi, (unknown), Ruping Shao, Jing Wang, Yang Zhao, Veerabhadran Baladandayuthapani, Juhee Song, Bingliang Fang, Lin Ji, Reza J. Mehran, Jack A. Roth	21
12	Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy 2015 ·PLoS ONE ·Bingbing Dai, Shaoyu Yan, Humberto Lara-Guerra, Hiroyuki Kawashima, Ryo Sakai, Gitanjali Jayachandran, Mourad Majidi, Reza J. Mehran, Jing Wang, B. Nebiyou Bekele, Veerabhadran Baladandayuthapani, Suk-Young Yoo, Ying Wang, Binwu Ying, Feng Meng, Lin Ji, Jack A. Roth	27
13	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells 2015 ·Oncotarget ·Hongyu Li, Jing Hu, Shuhong Wu, Li Wang, (unknown), Xiaoshan Zhang, Bingbing Dai, Mengru Cao, Ruping Shao, Ran Zhang, Mourad Majidi, Lin Ji, John V. Heymach, Michael Wang, Shiyang Pan, John D. Minna, Reza J. Mehran, Stephen G. Swisher, Jack A. Roth, Bingliang Fang	128
14	KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer 2013 ·Cancer Research ·Bingbing Dai, Suk-Young Yoo, Geoffrey Bartholomeusz, (unknown), Mourad Majidi, Shaoyu Yan, Jieru Meng, Lin Ji, Kevin R. Coombes, John D. Minna, Bingliang Fang, Jack A. Roth	55
15	The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner 2013 ·PLoS ONE ·Jieru Meng, Mourad Majidi, Bingliang Fang, Lin Ji, B. Nebiyou Bekele, John D. Minna, Jack A. Roth	16
16	Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma 2008 ·Carcinogenesis ·Hildegard M. Schuller, Hussein A.N. Al-Wadei, Mourad Majidi	111
17	NNK activates ERK1/2 and CREB/ATF‐1 via β‐1‐AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells 2006 ·International Journal of Cancer ·(unknown), Mourad Majidi, Maria Cekanova, Thomas Masi, Takashi Takahashi, (unknown)	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact